Reports, Volume 4, Issue 1
2021 March - 8 articles
Cover Story: The immune system has complementary functions, defending the organism from bacteria, viruses, or tumor cells (immune response), but also following a narrow line, it identifies and respects its own structures. For this immunological tolerance, there are key points such as CTLA-4 or PD-1 that modulate the activation of the immune system. Blocking these pathways with Tremelimumab (anti-CTLA-4 antibody) or Durvalumab (anti-PD-L1 antibody), immune response against cancer is boosted, but autoimmune diseases are frequently triggered by breaking previous immune tolerance as adverse events. View this paper
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Articles
There are no articles in this issue yet.
Reports - ISSN 2571-841X